{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T19:33:28Z","timestamp":1791401608990,"version":"4.3.3"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,1,2]],"date-time":"2021-01-02T00:00:00Z","timestamp":1609545600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Contemporary Clinical Trials Communications"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.conctc.2021.100702","type":"journal-article","created":{"date-parts":[[2021,1,10]],"date-time":"2021-01-10T08:14:38Z","timestamp":1610266478000},"page":"100702","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Demographic representation in clinical trials for cell-based therapy"],"prefix":"10.1016","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0494-3869","authenticated-orcid":false,"given":"Russell G.","family":"Saltzman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dushyantha T.","family":"Jayaweera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina V.","family":"Caceres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1094-2571","authenticated-orcid":false,"given":"Jairo A.","family":"Tovar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayra","family":"Vidro-Casiano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vela","family":"Karakeshishyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanette","family":"Soto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aisha","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raul D.","family":"Mitrani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2814-2321","authenticated-orcid":false,"given":"Ivonne H.","family":"Schulman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua M.","family":"Hare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.conctc.2021.100702_bib1","series-title":"Public Health Service Act","year":"2007"},{"issue":"9","key":"10.1016\/j.conctc.2021.100702_bib2","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1161\/CIRCRESAHA.118.310426","article-title":"Interdisciplinary stem cell Institute at the University of Miami miller School of medicine","volume":"123","author":"Schulman","year":"2018","journal-title":"Circ. Res."},{"issue":"1","key":"10.1016\/j.conctc.2021.100702_bib3","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1089\/jwh.2005.14.19","article-title":"Sex and racial differences in pharmacological response: where is the evidence? Pharmacogenetics, pharmacokinetics, and pharmacodynamics","volume":"14","author":"Anderson","year":"2005","journal-title":"J. Womens Health (Larchmt)"},{"key":"10.1016\/j.conctc.2021.100702_bib4","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1146\/annurev.pharmtox.44.101802.121453","article-title":"Sex differences in pharmacokinetics and pharmacodynamics","volume":"44","author":"Gandhi","year":"2004","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"issue":"1","key":"10.1016\/j.conctc.2021.100702_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40246-014-0023-x","article-title":"Self-reported race\/ethnicity in the age of genomic research: its potential impact on understanding health disparities","volume":"9","author":"Mersha","year":"2015","journal-title":"Hum. Genom."},{"issue":"16","key":"10.1016\/j.conctc.2021.100702_bib6","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1056\/NEJMra0911564","article-title":"Ancestry and disease in the age of genomic medicine","volume":"363","author":"Rotimi","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"14","key":"10.1016\/j.conctc.2021.100702_bib7","doi-asserted-by":"crossref","first-page":"e1328","DOI":"10.1212\/WNL.0000000000008194","article-title":"Sex differences by design and outcome in the Safety of Urate Elevation in PD (SURE-PD) trial","volume":"93","author":"Schwarzschild","year":"2019","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.conctc.2021.100702_bib8","doi-asserted-by":"crossref","first-page":"E29","DOI":"10.1208\/ps050429","article-title":"Pharmacogenomics of multigenic diseases: sex-specific differences in disease and treatment outcome","volume":"5","author":"Pinsonneault","year":"2003","journal-title":"AAPS PharmSci"},{"issue":"13","key":"10.1016\/j.conctc.2021.100702_bib9","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1093\/cvr\/cvaa004","article-title":"The impact of patient sex on the response to intramyocardial mesenchymal stem cell administration in patients with non-ischemic dilated cardiomyopathy","volume":"116","author":"Florea","year":"2020","journal-title":"Cardiovasc. Res."},{"issue":"12","key":"10.1016\/j.conctc.2021.100702_bib10","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001918","article-title":"Diversity in clinical and biomedical research: a promise yet to be fulfilled","volume":"12","author":"Oh","year":"2015","journal-title":"PLoS Med."},{"key":"10.1016\/j.conctc.2021.100702_bib11","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.ebiom.2019.09.043","article-title":"Genetic determinants of responsiveness to mesenchymal stem cell injections in non-ischemic dilated cardiomyopathy","volume":"48","author":"Rieger","year":"2019","journal-title":"EBioMedicine"},{"issue":"2","key":"10.1016\/j.conctc.2021.100702_bib12","doi-asserted-by":"crossref","first-page":"265","DOI":"10.5966\/sctm.2015-0232","article-title":"Inequality issues in stem cell medicine","volume":"5","author":"Yap","year":"2016","journal-title":"Stem Cells Transl. Med."},{"issue":"4","key":"10.1016\/j.conctc.2021.100702_bib13","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1089\/jwh.2016.6272","article-title":"Representation of women and minorities in clinical trials for new molecular entities and original therapeutic biologics approved by FDA CDER from 2013 to 2015","volume":"27","author":"Chen","year":"2018","journal-title":"J. Womens Health (Larchmt)"},{"key":"10.1016\/j.conctc.2021.100702_bib14","doi-asserted-by":"crossref","DOI":"10.1038\/s41536-019-0083-6","article-title":"Mesenchymal stem cell perspective: cell biology to clinical progress","volume":"4","author":"Pittenger","year":"2019","journal-title":"NPJ Regen. Med."},{"issue":"8 Suppl","key":"10.1016\/j.conctc.2021.100702_bib15","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1016\/S1047-2797(00)00199-X","article-title":"Minority recruitment in clinical trials: a conference at Tuskegee, researchers and the community","volume":"10","author":"Fouad","year":"2000","journal-title":"Ann. Epidemiol."},{"issue":"23","key":"10.1016\/j.conctc.2021.100702_bib16","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1093\/jnci\/87.23.1747","article-title":"Recruiting minorities into clinical trials: toward a participant-friendly system","volume":"87","author":"Swanson","year":"1995","journal-title":"J. Natl. Cancer Inst."},{"issue":"7","key":"10.1016\/j.conctc.2021.100702_bib17","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1001\/jama.1992.03480070070033","article-title":"The challenge of minority recruitment in clinical trials for AIDS","volume":"267","author":"el-Sadr","year":"1992","journal-title":"J. Am. Med. Assoc."},{"issue":"6 Suppl 1","key":"10.1016\/j.conctc.2021.100702_bib18","doi-asserted-by":"crossref","first-page":"S195","DOI":"10.1016\/j.amepre.2009.08.006","article-title":"Effective recruitment of minority populations through community-led strategies","volume":"37","author":"Horowitz","year":"2009","journal-title":"Am. J. Prev. Med."},{"issue":"8","key":"10.1016\/j.conctc.2021.100702_bib19","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1161\/CIRCRESAHA.114.303180","volume":"114","author":"Karantalis","year":"2014","journal-title":"Circ. Res."},{"issue":"22","key":"10.1016\/j.conctc.2021.100702_bib20","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1001\/jama.2012.25321","article-title":"Comparison of allogeneic vs autologous bone marrow-derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial","volume":"308","author":"Hare","year":"2012","journal-title":"J. Am. Med. Assoc."},{"issue":"5","key":"10.1016\/j.conctc.2021.100702_bib21","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.jacc.2016.11.009","article-title":"Randomized Comparison of allogeneic versus autologous mesenchymal stem cells for nonischemic dilated cardiomyopathy: POSEIDON-DCM trial","volume":"69","author":"Hare","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"issue":"1","key":"10.1016\/j.conctc.2021.100702_bib22","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1001\/jama.2013.282909","article-title":"Transendocardial mesenchymal stem cells and mononuclear bone marrow cells for ischemic cardiomyopathy: the TAC-HFT randomized trial","volume":"311","author":"Heldman","year":"2014","journal-title":"J. Am. Med. Assoc."},{"issue":"11","key":"10.1016\/j.conctc.2021.100702_bib23","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1161\/CIRCRESAHA.117.311827","article-title":"Dose Comparison study of allogeneic mesenchymal stem cells in patients with ischemic cardiomyopathy (the TRIDENT study)","volume":"121","author":"Florea","year":"2017","journal-title":"Circ. Res."},{"issue":"5","key":"10.1016\/j.conctc.2021.100702_bib24","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.chest.2016.10.061","article-title":"Allogeneic human mesenchymal stem cells in patients with idiopathic pulmonary fibrosis via intravenous delivery (AETHER): a phase I safety clinical trial","volume":"151","author":"Glassberg","year":"2017","journal-title":"Chest"},{"issue":"11","key":"10.1016\/j.conctc.2021.100702_bib25","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1093\/gerona\/glx056","article-title":"Allogeneic human mesenchymal stem cell infusions for aging frailty","volume":"72","author":"Golpanian","year":"2017","journal-title":"J. Gerontol. A Biol. Sci. Med. Sci."},{"issue":"11","key":"10.1016\/j.conctc.2021.100702_bib26","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1093\/gerona\/glx137","article-title":"Allogeneic mesenchymal stem cells ameliorate aging frailty: a phase II randomized, double-blind, placebo-controlled clinical trial","volume":"72","author":"Tompkins","year":"2017","journal-title":"J. Gerontol. A Biol. Sci. Med. Sci."},{"key":"10.1016\/j.conctc.2021.100702_bib27","unstructured":"University Research Informatics Data Environment. (Available from: miamictsi.org\/researchers\/research-tools\/uride)."},{"issue":"6","key":"10.1016\/j.conctc.2021.100702_bib28","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1097\/MJT.0000000000000177","article-title":"Demographics of clinical trials participants in pivotal clinical trials for new molecular entity drugs and biologics approved by FDA from 2010 to 2012","volume":"22","author":"Eshera","year":"2015","journal-title":"Am. J. Therapeut."},{"key":"10.1016\/j.conctc.2021.100702_bib29","series-title":"Stromal Cells - Structure, Function, and Therapeutic Implications","first-page":"143","article-title":"Mesenchymal stromal cells as a therapeutic intervention","author":"Schulman","year":"2018"},{"issue":"1","key":"10.1016\/j.conctc.2021.100702_bib30","doi-asserted-by":"crossref","first-page":"708","DOI":"10.18549\/PharmPract.2016.01.708","article-title":"Women\u2019s involvement in clinical trials: historical perspective and future implications","volume":"14","author":"Liu","year":"2016","journal-title":"Pharm. Pract. (Granada)"},{"issue":"6","key":"10.1016\/j.conctc.2021.100702_bib31","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1111\/j.1525-1497.2006.00485.x","article-title":"Understanding African Americans\u2019 views of the trustworthiness of physicians","volume":"21","author":"Jacobs","year":"2006","journal-title":"J. Gen. Intern. Med."},{"issue":"2","key":"10.1016\/j.conctc.2021.100702_bib32","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.cct.2014.08.004","article-title":"Strategies addressing barriers to clinical trial enrollment of underrepresented populations: a systematic review","volume":"39","author":"Heller","year":"2014","journal-title":"Contemp. Clin. Trials"},{"issue":"4","key":"10.1016\/j.conctc.2021.100702_bib38","first-page":"581","article-title":"Allogeneic mesenchymal cell therapy in anthracycline-induced cardiomyopathy heart failure patients. The CCTRN SENECA trial","volume":"2","author":"Bolli","year":"2020","journal-title":"JACC: CardioOncol."},{"issue":"18","key":"10.1016\/j.conctc.2021.100702_bib33","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1016\/j.jacc.2018.02.070","article-title":"Participation of women in clinical trials supporting FDA approval of cardiovascular drugs","volume":"71","author":"Scott","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.conctc.2021.100702_bib34","unstructured":"21st Century Cures Act, 2016. 42 U.S.C. 201, Pub.L. 114-255."},{"key":"10.1016\/j.conctc.2021.100702_bib35","author":"NIH"},{"issue":"2","key":"10.1016\/j.conctc.2021.100702_bib36","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1086\/493243","article-title":"Hippocrates: \u201cDiseases of Women 1\u201d","volume":"1","author":"Hanson","year":"1975","journal-title":"Signs: J. Women Cult. Soc."},{"key":"10.1016\/j.conctc.2021.100702_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2019.100249","article-title":"Cell therapy with intravascular administration of mesenchymal stromal cells continues to appear safe: an updated systematic review and meta-analysis","volume":"19","author":"Thompson","year":"2020","journal-title":"EClinicalMedicine"}],"container-title":["Contemporary Clinical Trials Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2451865421000053?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2451865421000053?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T13:05:21Z","timestamp":1762520721000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2451865421000053"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":38,"alternative-id":["S2451865421000053"],"URL":"https:\/\/doi.org\/10.1016\/j.conctc.2021.100702","relation":{},"ISSN":["2451-8654"],"issn-type":[{"value":"2451-8654","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Demographic representation in clinical trials for cell-based therapy","name":"articletitle","label":"Article Title"},{"value":"Contemporary Clinical Trials Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.conctc.2021.100702","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100702"}}